Mr. Gruener is a co-founder of Alta, and was also a Partner at Burr, Egan, Deleage & Co. He served as the Chief Executive Officer at Nanōmix from 2008 to 2013 and has more than two decades of experience in the fields of software development, systems engineering and corporate development. In 1982, he founded Virtual Microsystems, a successful communications software company that was later merged with a larger corporation. Garrett also founded Ask Jeeves, now Ask.Com, a leading Internet search engine which is now part of IAC. Garrett specializes in information technology and is on the board of directors of nCircle Network Security and Xelerated. He earned a Masters Degree from the University of California, Berkeley and a Bachelor of Science from the University of California, San Diego, both in Political Science with a focus on technology policy.
Dr. Schlumpberger is a recognized expert in POC diagnostics and a seasoned senior executive with more than 20 years in the life sciences industry. His broad base of experience is directly applicable to the next phase of growth at Nanōmix as the Company’s POC platform gains customer adoption. At Epocal, a POC company, he was responsible for international business and business development. He successfully launched a point-of-care product in India, Japan and Europe and, notably, he led the sale of Epocal to Alere. At Singulex, he concluded an investment from Grifols and successfully launched an ultra-high sensitivity assay in Europe. Most recently, as CEO of Pictor Limited, he successfully revamped the product portfolio and launched a COVID-19 antibody product successfully into several CLIA-certified laboratories. Dr. Schlumpberger has held senior executive roles with several other diagnostic companies, including Anixa, InVitae, Inivata, and Affymetrix. He received his Ph.D. in molecular and cell biology with distinction from the University of California, Berkeley.
Mr. Hetterly is a financial executive and entrepreneur, with over 25 years of financial leadership and banking experience. Previously, Mr. Hetterly was the CFO of Octagos Health, a healthcare Software-as-a-Service (SaaS) company. Prior to that, he was a CFO at Madrona Ventures portfolio companies. Mr. Hetterly was the Head of Technology Finance at GE Capital, Wells Fargo, and East West Bank, in addition to being CFO/CIO at Palo Alto Capital. He has raised capital from seed stage to IPO and beyond, and has experience in debt and equity financing, corporate development, business development, with particular expertise in building finance teams and leading in high growth environments. Mr. Hetterly has raised over $10 billion in capital in his career for well-known names such as eBay, Netflix and Symantec amongst others, and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. He graduated from Brown University with a BA from the Honors Program.
Mr. Hardesky is an accomplished leader with over 20 years of commercialization experience in the clinical diagnostics market. John has built a strong track record of innovative concept to execution strategies that yield turnaround and growth results. While holding leadership positions in manufacturer and distribution, start-up through large companies, he launched over 20 different product platforms and value-based solutions to market. John is passionate about creating a culture of entrepreneurial spirited drive with execution confidence.
Vidur brings more than 23 years of experience in operations, quality, validation, manufacturing, and research. His experience includes FDA Class II and Class III / PMA and CE product approvals and commercialization activities. He has set up and scaled production, technical operations, and supply chains in several companies, including ExThera Medical, JUUL Labs, Thoratec, and Loma Vista Medical which have led to multiple exits. He holds a Mechanical Engineering degree and was trained in Six Sigma Lean Manufacturing by Toyota.
Mr. Johnson has more than 10 years of broad experience in biotechnology and biomedical devices. His primary focus is in vitro diagnostic methods, related instrumentation and technology including microfluidics and electro chemical biosensors. He received his Ph.D. in Bioengineering from University of California, Berkeley.
Mr. Gruener is a co-founder of Alta, and was also a Partner at Burr, Egan, Deleage & Co. He served as the Chief Executive Officer at Nanōmix from 2008 to 2013 and has more than two decades of experience in the fields of software development, systems engineering and corporate development. In 1982, he founded Virtual Microsystems, a successful communications software company that was later merged with a larger corporation. Garrett also founded Ask Jeeves, now Ask.Com, a leading Internet search engine which is now part of IAC. Garrett specializes in information technology and is on the board of directors of nCircle Network Security and Xelerated. He earned a Masters Degree from the University of California, Berkeley and a Bachelor of Science from the University of California, San Diego, both in Political Science with a focus on technology policy.
Dr. Schlumpberger is a recognized expert in POC diagnostics and a seasoned senior executive with more than 20 years in the life sciences industry. His broad base of experience is directly applicable to the next phase of growth at Nanōmix as the Company’s POC platform gains customer adoption. At Epocal, a POC company, he was responsible for international business and business development. He successfully launched a point-of-care product in India, Japan and Europe and, notably, he led the sale of Epocal to Alere. At Singulex, he concluded an investment from Grifols and successfully launched an ultra-high sensitivity assay in Europe. Most recently, as CEO of Pictor Limited, he successfully revamped the product portfolio and launched a COVID-19 antibody product successfully into several CLIA-certified laboratories. Dr. Schlumpberger has held senior executive roles with several other diagnostic companies, including Anixa, InVitae, Inivata, and Affymetrix. He received his Ph.D. in molecular and cell biology with distinction from the University of California, Berkeley.
Mr. Ludvigson is a financial and operating executive, and entrepreneur, with over 35 years of international experience in life sciences and technology companies including IDEC Pharmaceuticals, Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems. He has over 20 years of Life Science experience including more than 15 years in the diagnostics arena and has led numerous new product efforts from concept to market launch. Mr. Ludvigson has concluded many successful strategic transactions including multiple acquisitions, corporate partnerships, technology and intellectual property licensing agreements, and OEM relationships and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. Mr. Ludvigson holds both a BA and MAS from the University of Illinois.
Mr. Schiffman is a CPA and an accomplished senior finance executive with more than 25 years of strategic and operational finance, treasury, corporate development and manufacturing operations experience. He has served as Chief Financial Officer at Iovance, as Executive Vice President and Chief Financial Officer at StemCells, Inc., Dendreon, and Affymetrix, all publicly-traded healthcare companies as well as Vineti a private SaaS company supporting supply chain requirements for cellular therapies. Notably, while serving as Executive Vice President and CFO of Dendreon Corporation, the company secured marketing authorization from the FDA and the European Commission for the world’s first cell-based, autologous immunotherapy for prostate cancer. Prior to these roles, he was Vice President and Controller at Applied BioSystems where he managed global financial operations and headed up a variety of global assignments at Hewlett Packard including international finance projects in Europe and Asia, and a U.S. manufacturing operation. He is on the board of directors of BioEclipse and DropCar. Mr. Schiffman received an M.B.A. from Northwestern University and holds a bachelor’s degree in accounting from De Paul University.
Mr. Fiddler is the principal of Zygote Ventures and has helped create and grow numerous companies, as CEO, chairman, director, investor and advisor. Mr. Fiddler is the founder of Wind River and was for 23 years its CEO and Chairman. He is currently the Chairman of Solazyme (Nasdaq:SZYM).
Dr. Lazarus has led multiple organizations as Chief Medical Officer encompassing biochemistry, medical diagnostics, and patient services arenas. Companies include Achieve Health Management, Inivata Inc., and Clinical Genomics. He served as Chief Medical Officer and Head of Medical & Scientific Affairs, Reimbursement, and Public Policy at Qiagen from 2013 through 2016. In 2010, Lazarus was at Gen-Probe Inc., (now Hologic), as Chief Medical Officer and VP of Clinical Affairs, where he was responsible for a 42-person team dedicated to clinical trials. Lazarus began his career at Roche Diagnostics, where he held simultaneous roles in private practice and as Director of Medical and Scientific Affairs, and then as the North American Medical Director for the molecular diagnostics, POC, diabetes, clinical chemistry, and immunology lines of business. Dr. Lazarus received a Bachelor of Science in Biology & Physiology from Marlboro College and earned his Medical Degree from Ross University School of Medicine.